11/17
08:06 am
advm
Adverum Biotechnologies (NASDAQ:ADVM) had its "neutral" rating reaffirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock, down previously from $30.00.
Low
Report
Adverum Biotechnologies (NASDAQ:ADVM) had its "neutral" rating reaffirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock, down previously from $30.00.
11/17
06:11 am
advm
Adverum Biotechnologies downgraded to Neutral from Buy at H.C. Wainwright
Low
Report
Adverum Biotechnologies downgraded to Neutral from Buy at H.C. Wainwright
11/17
06:11 am
advm
Adverum Biotechnologies downgraded to Neutral from Buy at H.C. Wainwright
Low
Report
Adverum Biotechnologies downgraded to Neutral from Buy at H.C. Wainwright
10/28
05:30 pm
advm
Rating for ADVM
Low
Report
Rating for ADVM
10/28
05:30 pm
advm
Rating for ADVM
Low
Report
Rating for ADVM
10/28
10:59 am
advm
Adverum Biotechnologies (NASDAQ:ADVM) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.
Low
Report
Adverum Biotechnologies (NASDAQ:ADVM) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.
10/28
10:59 am
advm
Adverum Biotechnologies (NASDAQ:ADVM) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.
Low
Report
Adverum Biotechnologies (NASDAQ:ADVM) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.
10/28
06:18 am
advm
Adverum Biotechnologies (NASDAQ:ADVM) was downgraded by analysts at Chardan Capital from a "strong-buy" rating to a "hold" rating.
Medium
Report
Adverum Biotechnologies (NASDAQ:ADVM) was downgraded by analysts at Chardan Capital from a "strong-buy" rating to a "hold" rating.
10/24
09:06 pm
advm
Adverum Biotechnologies downgraded to Neutral from Buy at Chardan
Medium
Report
Adverum Biotechnologies downgraded to Neutral from Buy at Chardan
9/23
08:07 am
advm
Adverum Biotechnologies (NASDAQ:ADVM) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
High
Report
Adverum Biotechnologies (NASDAQ:ADVM) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.